A retrospective study demonstrating high diagnostic accuracy of the 23-GEP in diagnostically uncertain cases when evaluated against clinical outcomes

Systematic review of available evidence on GEP for prognosis. Included meta-analysis of 6 studies on the 31-GEP. Clinical implications show that 31-GEP can better assess prognosis leading to more appropriate patient management.

An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.

TissueCypher stratified BE patients with a community-based diagnosis of LGD with diagnostic accuracy comparable to three renowned expert pathologists.

TissueCypher provided superior risk stratification that outperformed crypt atypia scores.

To develop and validate a gene expression profile (GEP) test for predicting risk for metastasis in localized, high-risk cSCC with the goal of improving risk-directed patient management.

Meta-analysis stage I-II patients. GEP consistently identifies melanoma patients at increased risk of metastasis, independent of clinicopathologic features and can be used in conjunction with traditional staging to improve patient risk stratification.

This guideline reviews the evidence for the use of definitive and postoperative radiation therapy (RT) in patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).

TissueCypher may be a effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.

The TissueCypher assay would be cost-effective after 5 years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.

To determine the impact of cSCC-GEP test results on management decisions made by dermatologists for cSCC patients.

Expert panel of 9 dermatologists developed 29 clinical scenarios creating an evidence based framework for AUC recommendations for integration of melanoma GEP tests into clincial practice